[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100380386":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":30,"centralContacts":31,"locations":40,"responsibleParty":196,"collaborators":30,"id":198,"slug":30,"hasResults":199,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":203,"eligibilityCriteria":204,"healthyVolunteers":199,"sex":205,"minAge":206,"maxAge":207,"enrollmentInfo":208,"targetDuration":30,"studyType":211,"phases":212,"briefSummary":214,"conditions":215,"keywords":30,"overallStatus":43,"whyStopped":30,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":226},{"fullName":5,"class":6},"Labo'Life","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"2LPAPI® arm","EXPERIMENTAL","The treatment schema consists in taking the content of one capsule a day, 15-30 minutes before breakfast, on an empty stomach, sequentially, according to capsules' numerical order: 1 through 10. When capsule number 10 is taken, capsule 1 of the next blister should be taken on the next day to continue the treatment. The duration of treatment will be 6 months of continuous intake of the content of 1 capsule\u002Fday.",[13],"Drug: 2LPAPI®",{"label":15,"type":16,"description":11,"interventionNames":17},"Placebo arm","PLACEBO_COMPARATOR",[18],"Drug: Placebo",[20,27],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","2LPAPI®","Treatment",[9],[26],"2LPAPI",{"type":21,"name":28,"description":28,"armGroupLabels":29,"otherNames":30},"Placebo",[15],null,[32,37],{"name":33,"role":34,"phone":35,"phoneExt":30,"email":36},"Laura FERTE","CONTACT","+32499717964","laura.ferte@labolife.com",{"name":38,"role":34,"phone":30,"phoneExt":30,"email":39},"Charlotte BOLLE","charlotte.bolle@labolife.com",[41,65,82,96,109,119,128,140,144,153,165,179],{"facility":42,"status":43,"city":44,"state":30,"zip":45,"country":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"CHU Saint-Pierre","RECRUITING","Brussels","1000","Belgium",{"type":48,"coordinates":49},"Point",[50,51],4.34878,50.85045,{"lat":51,"lon":50},[54,56,58,61,63],{"name":55,"role":34,"phone":30,"phoneExt":30,"email":30},"Yannick Manigart, Dr",{"name":55,"role":57,"phone":30,"phoneExt":30,"email":30},"PRINCIPAL_INVESTIGATOR",{"name":59,"role":60,"phone":30,"phoneExt":30,"email":30},"Aurélie Joris, Dr","SUB_INVESTIGATOR",{"name":62,"role":60,"phone":30,"phoneExt":30,"email":30},"Christine Gilles, Dr",{"name":64,"role":60,"phone":30,"phoneExt":30,"email":30},"Charlotte Rousseau, Dr",{"facility":66,"status":43,"city":44,"state":30,"zip":45,"country":46,"cosmosGeoPoint":67,"geoPoint":69,"contacts":70},"Clinique St Jean",{"type":48,"coordinates":68},[50,51],{"lat":51,"lon":50},[71,73,75,77,79,81],{"name":72,"role":34,"phone":30,"phoneExt":30,"email":30},"Nathanaël DUBOIS",{"name":74,"role":60,"phone":30,"phoneExt":30,"email":30},"Jean-Paul VAN GOSSUM",{"name":76,"role":60,"phone":30,"phoneExt":30,"email":30},"Justine JEHOTTE",{"name":78,"role":60,"phone":30,"phoneExt":30,"email":30},"Andrea RADULESCU",{"name":80,"role":60,"phone":30,"phoneExt":30,"email":30},"Mathilde BARREIRA",{"name":72,"role":57,"phone":30,"phoneExt":30,"email":30},{"facility":83,"status":43,"city":44,"state":30,"zip":84,"country":46,"cosmosGeoPoint":85,"geoPoint":87,"contacts":88},"CHU Brugmann","1020",{"type":48,"coordinates":86},[50,51],{"lat":51,"lon":50},[89,91,93,95],{"name":90,"role":34,"phone":30,"phoneExt":30,"email":30},"Tatiana Besse-Hammer, MD",{"name":92,"role":57,"phone":30,"phoneExt":30,"email":30},"Catherine Van Pachterbeke, MD",{"name":94,"role":60,"phone":30,"phoneExt":30,"email":30},"Elie Finianos, MD",{"name":90,"role":60,"phone":30,"phoneExt":30,"email":30},{"facility":97,"status":43,"city":44,"state":30,"zip":98,"country":46,"cosmosGeoPoint":99,"geoPoint":101,"contacts":102},"Hôpitaux Iris Sud - Iris Zuid Ziekenhuis","1050",{"type":48,"coordinates":100},[50,51],{"lat":51,"lon":50},[103,105,107],{"name":104,"role":34,"phone":30,"phoneExt":30,"email":30},"Frédéric BUXANT, MD",{"name":106,"role":57,"phone":30,"phoneExt":30,"email":30},"Frédéric Buxant, MD",{"name":108,"role":60,"phone":30,"phoneExt":30,"email":30},"Fiona Avau, MD",{"facility":110,"status":111,"city":112,"state":30,"zip":113,"country":46,"cosmosGeoPoint":114,"geoPoint":118,"contacts":30},"Hôpital Civil Marie Curie ISPPC","ACTIVE_NOT_RECRUITING","Charleroi","6042",{"type":48,"coordinates":115},[116,117],4.44448,50.41136,{"lat":117,"lon":116},{"facility":120,"status":111,"city":121,"state":30,"zip":122,"country":46,"cosmosGeoPoint":123,"geoPoint":127,"contacts":30},"Centre Hospital Reine Astrid Malmedy (CHRAM)","Malmedy","4960",{"type":48,"coordinates":124},[125,126],6.02794,50.42686,{"lat":126,"lon":125},{"facility":46,"status":43,"city":129,"state":30,"zip":130,"country":46,"cosmosGeoPoint":131,"geoPoint":135,"contacts":136},"Namur","5000",{"type":48,"coordinates":132},[133,134],4.86746,50.4669,{"lat":134,"lon":133},[137,139],{"name":138,"role":34,"phone":30,"phoneExt":30,"email":30},"Sarah MITRI",{"name":138,"role":57,"phone":30,"phoneExt":30,"email":30},{"facility":46,"status":111,"city":129,"state":30,"zip":130,"country":46,"cosmosGeoPoint":141,"geoPoint":143,"contacts":30},{"type":48,"coordinates":142},[133,134],{"lat":134,"lon":133},{"facility":145,"status":43,"city":129,"state":30,"zip":130,"country":46,"cosmosGeoPoint":146,"geoPoint":148,"contacts":149},"Cabinet privé",{"type":48,"coordinates":147},[133,134],{"lat":134,"lon":133},[150,152],{"name":151,"role":34,"phone":30,"phoneExt":30,"email":30},"Benoit MOONS",{"name":151,"role":57,"phone":30,"phoneExt":30,"email":30},{"facility":154,"status":43,"city":129,"state":30,"zip":30,"country":46,"cosmosGeoPoint":155,"geoPoint":157,"contacts":158},"UCL Namur - site Sainte Elisabeth",{"type":48,"coordinates":156},[133,134],{"lat":134,"lon":133},[159,161,163,164],{"name":151,"role":34,"phone":30,"phoneExt":30,"email":160},"benoit.moons@chuuclnamur.uclouvain.be",{"name":162,"role":34,"phone":30,"phoneExt":30,"email":30},"MD",{"name":151,"role":57,"phone":30,"phoneExt":30,"email":30},{"name":138,"role":60,"phone":30,"phoneExt":30,"email":30},{"facility":166,"status":167,"city":168,"state":30,"zip":169,"country":46,"cosmosGeoPoint":170,"geoPoint":174,"contacts":175},"Clinique Saint-Pierre Ottignies (CSPO)","NOT_YET_RECRUITING","Ottignies","1340",{"type":48,"coordinates":171},[172,173],4.56679,50.66535,{"lat":173,"lon":172},[176,178],{"name":177,"role":34,"phone":30,"phoneExt":30,"email":30},"Lucie Verreth, Dr",{"name":177,"role":57,"phone":30,"phoneExt":30,"email":30},{"facility":180,"status":43,"city":181,"state":30,"zip":182,"country":46,"cosmosGeoPoint":183,"geoPoint":187,"contacts":188},"CHWAPI","Tournai","7000",{"type":48,"coordinates":184},[185,186],3.38932,50.60715,{"lat":186,"lon":185},[189,191,193,195],{"name":190,"role":34,"phone":30,"phoneExt":30,"email":30},"Marc WAYEMBERGH, MD",{"name":192,"role":60,"phone":30,"phoneExt":30,"email":30},"Céline PETIT, MD",{"name":194,"role":60,"phone":30,"phoneExt":30,"email":30},"Sandra TASSART, MD",{"name":190,"role":57,"phone":30,"phoneExt":30,"email":30},{"type":197,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100380386",false,"NCT04232917","Study of 2LPAPI® on the Clearance of Genital HR-HPV Infections.","Randomized, Placebo-controlled, Double-blind Study to Evaluate 2LPAPI® Efficacy on the Clearance of Genital HR-HPV Infections.","PAPION","Inclusion Criteria:\n\n* Women 25-45 years,\n* Women of childbearing age under effective contraception,\n* Patient with last cytology less than 3 years and normal or not more than LSIL or CIN I at the histology,\n* Patient with current cytology presenting normal, ASC-US, AGUS, LSIL, ASC-H, AGC or LSIL+ASC-H results or current diagnosis of CIN I at the histology,\n* Patient with HR-HPV diagnosis at the current cervical collection,\n* Patient reporting a current stable sexual relationship (steady sexual partner during study duration),\n* Patient having faculties to understand and respect the constraints of the study,\n* Signature of the Informed Consent Form.\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding woman,\n* Patient presenting HSIL diagnosis at the cytology or CIN II or CIN III diagnosis at the histology,\n* Patient having received HPV vaccination in the last month,\n* Patient previously subject to total hysterectomy,\n* Patient under immunotherapy (including immunosuppressive treatment) or micro-immunotherapy received during last previous 6 months,\n* Patient with known lactose intolerance,\n* Patient who participated in a clinical study in the previous 3-months' period,\n* Patient who is not sufficiently motivated to engage in a follow-up period of 12 months, or likely to travel or to move before the end of the study,\n* Patient with severe immunodeficiency disease requiring long term treatment (\\*) or under chemotherapy or radiotherapy,\n* Patient under listed homeopathic or phytotherapy treatment (see protocol),\n* Patient using or addicted to recreational drugs.\n\n(\\*) important renal or respiratory insufficiency, transplanted or grafted patients, HIV\u002FAIDS, terminal cancer.","FEMALE","25 Years","45 Years",{"count":209,"type":210},284,"ESTIMATED","INTERVENTIONAL",[213],"PHASE4","Human papillomavirus (HPV) is a prevalent pathogen, the epidemiology of which has mostly been studied in the uterine cervix and the vagina.\n\nThe KCE Report 238Cs (2015) recommends \" HR-HPV-positive women should not be offered colposcopy immediately. Triage should be done using cytology for this purpose. If cytological abnormalities (ASCUS+) are found, immediate referral should follow for diagnosis and, where appropriate, treatment. If no abnormalities are observed in triage, the subject should be offered follow-up testing (cytology) at six months. \".\n\nThere is no treatment that is recommended during this lap time. The 2LPAPI® has been available for more than 20 years, and has received a marketing authorization in Belgium by the FAMHP. It is used as an immune regulator in the treatment of HR-HPV infections. Since 2LPAPI® has been made available, clinical observational data collected on treated patients have shown the beneficial effect on the clearance of HPV.\n\nThe purpose of this placebo-controlled trial is to evaluate the efficacy of 2LPAPI® on the clearance of genital HR-HPV infections.",[216],"Human Papilloma Virus","2024-10-29",{"date":219,"type":220},"2024-10-31","ACTUAL",{"date":222,"type":220},"2020-10-17",{"date":224,"type":210},"2027-10-30",{"name":5,"class":6},12]